Back to top
more

Lexicon Pharmaceuticals (LXRX)

(Delayed Data from NSDQ)

$1.75 USD

1.75
1,045,335

0.00 (0.00%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $1.75 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for LXRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Lexicon Pharmaceuticals, Inc. [LXRX]

Reports for Purchase

Showing records 201 - 220 ( 393 total )

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 201

05/31/2016

Company Report

Pages: 8

Telotristat NDA Accepted, Granted Priority Review, and PDUFA Set for 11/30; Reiterate OUTPERFORM but Raising PT to $30 for Reduced Regulatory Risk

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 202

05/31/2016

Daily Note

Pages: 43

June and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 203

05/27/2016

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of May 30

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 204

05/24/2016

Daily Note

Pages: 6

2016 Outlook: Lots of Cash, Major Catalysts and Reduced Risk; Reiterate OUTPERFORM and $28 Price Target.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 205

05/09/2016

Daily Note

Pages: 43

May and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 206

05/06/2016

Company Report

Pages: 8

Q1 Financial Update: 2016 Is Set to Be a Potential Value Creating Year; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 207

04/01/2016

Daily Note

Pages: 42

April and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 208

03/11/2016

Industry Report

Pages: 6

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 209

03/03/2016

Industry Report

Pages: 43

March and Full Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 210

03/01/2016

Company Report

Pages: 8

Q4/FY:15 Update; Several Potentially Material Catalysts in 2016; Reiterate OUTPERFORM and Raise PT to $28

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 211

01/31/2016

Daily Note

Pages: 39

February and Full-Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 212

01/29/2016

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 1This report contains brief updates on the following: SRPT, RGLS, BMRN, CBYL, CLDX, EPRS, LXRX, PCRX, PRTA, PTCT, RPTP, TTPH, RARE, VTAE, ICPT, CERU, FCSC, GBT, TSRO, TRVN, IRWD, MRTX, DNAI, XNCR. These companies are covered in more detail in separate Daily Notes and/or Company Reports.

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 213

12/31/2015

Daily Note

Pages: 42

Emerging Pharmaceuticals - January and Full-Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 214

12/07/2015

Daily Note

Pages: 46

December 2015 and Full-Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 215

12/07/2015

Daily Note

Pages: 46

December 2015 and Full-Year 2016 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 216

12/02/2015

Daily Note

Pages: 6

Positive Results From Confirmatory Phase 3 Trial for Telotristat Etiprate Position Company for NDA Filing in Q1:16; Reiterate OUTPERFORM and $26 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 217

12/02/2015

Company Report

Pages: 2

TELECAST Tells - Similar Story - Hold

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 218

11/20/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 23

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 219

11/09/2015

Company Report

Pages: 7

Sanofi Deal Resurrects T2DM for Sotagliflozin; Reiterate OUTPERFORM but Increasing Price Target to $26 for Increased Peak Sales Projection

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Lexicon Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 220

11/09/2015

Company Report

Pages: 2

Lexicon reported Q3 results

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party